TransThera Biosciences Co. Ltd
http://www.transtherabio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TransThera Biosciences Co. Ltd
2023 Review: Chinese-Sponsored Phase III US Trials See Uptick
Companies from China single-handedly sponsored a total of eight Phase III clinical studies that included US sites in 2023 compared to six in 2022 - but the figure was still below the record of 11 in 2021.
Chinese Biotech Financing Rebounds But Mega Deals Missing
Ten Chinese biotechs raised at least a combined $221m in venture capital and private equity deals after the turn of the year.
Oncology, Cell Therapy Developers Bag $175m In China
Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.
Asia Deal Watch: CANbridge Licenses Orphan Disease Candidates From Mirum, LogicBio
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Nanjing Transtherabio Sciences Co. Ltd.
- Nanjing TransThera Biosciences Co. Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice